Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

TARRYTOWN, N.Y. and PARIS , March 26, 2022 /PRNewswire/ -- Dupixent significantly reduced itch at 12 weeks, and at 24 weeks nearly three times as many Dupixent patients experienced clinically meaningful reductions in itch and skin lesions There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for Dupixent in prurigo nodularis are planned in the first half of 2022 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced that detailed positive results from the Phase 3 PRIME2 trial evaluating the efficacy and safety of Dupixent® (dupilumab) were presented today in a late-breaking session at the American Academy of Dermatology (AAD) 2022 Annual Meeting.

Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis

MercadoLibre

Tesla

These companies haven't said they'll split their stocks, but the topic should be on their minds.

3 Top Stock-Split Candidates After Amazon and Alphabet

Costco

Shopify

These stocks are all trading at more than $500.

Amazon Stock Split: 3 Companies That Should Follow Suit

88% technical buy signals. 8 new highs and up 15.01% in the last month.

Regeneron Searching For A New High

AstraZeneca

Revance Therapeutics

Should you be paying attention to these biotech stocks right now?

3 Top Biotech Stocks To Watch This Week

Regeneron (REGN) closed the most recent trading day at $665.93, moving +1.45% from the previous trading session.

Regeneron (REGN) Gains But Lags Market: What You Should Know

BioNTech SE

BioNTech (BNTX) expands its strategic collaboration deal with Regeneron to evaluate the combo of BNT116 plus Libtayo for treating advanced non-small cell lung cancer.

BioNTech (BNTX), Regeneron Expand Agreement for Lung Cancer Study

Pfizer

Vertex Pharmaceuticals

There's definitely a chance that we start to see some signs of life from top biotech stocks this month, which is why we've put together a list of the 3 best biotech stocks to buy in March below.

The 3 Best Biotech Stocks to Buy in March

BioNTech SE BNTX, -1.36% and Regeneron Pharmaceuticals Inc. REGN, -0.58% said they plan to test an experimental BioNTech cancer vaccine in combination with Regeneron's Libtayo in patients with advanced non-small cell lung cancer, starting with a Phase 1/2 clinical trial. Libtayo is approved in the U.S. to treat advanced basal cell carcinoma.

Regeneron, BioNTech to test experimental combination therapy for lung cancer

Coinbase

These companies are banking more than 30% of their revenue as profit.

2 Top Growth Stocks That Are Also Generating Billions in Free Cash

Merck

The WHO panel is also evaluating data for Pfizer's antiviral pill, paxlovid, and a widely available antidepressant, fluvoxamine, to treat Covid-19.

WHO Backs Merck's Antiviral Pill For High-Risk Covid Patients But Finds Regeneron's Antibody Cocktail ‘Ineffective' Against Omicron

Intellia Therapeutics

Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

TARRYTOWN, N.Y. and PARIS, Feb. 26, 2022 /PRNewswire/ --  Dupixent 300 mg weekly is the only biologic medicine to show positive, clinically meaningful Phase 3 results in adults and adolescents with eosinophilic esophagitis Eosinophilic esophagitis is a chronic, progressive type 2 inflammatory disease that damages the esophagus and prevents it from working properly   U.S. and global regulatory filings are planned in 2022 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive detailed results from a second Phase 3 trial that showed Dupixent® (dupilumab) 300 mg weekly significantly improved the signs and symptoms of eosinophilic esophagitis (EoE) at 24 weeks compared to placebo in patients 12 years and older.

Late-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic Esophagitis

TARRYTOWN, N.Y. and PARIS, Feb. 26, 2022 /PRNewswire/ -- In this Phase 3 trial, Dupixent added to standard-of-care antihistamines nearly doubled reduction in itch and urticaria activity scores compared to standard-of-care alone at 24 weeks in biologic-naïve patients uncontrolled on antihistamines Data reinforce the potential of targeting IL-4 and IL-13, key drivers of type 2 inflammation, in this complex chronic disease Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced detailed positive results for Dupixent® (dupilumab) in patients with chronic spontaneous urticaria (CSU) who are biologic-naïve (i.e.

Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria

Garmin

Infosys

Coca-Cola

Northrop Grumman

Texas Instruments

A great way to find low volatility stocks is to look for a beta that's less than 1.0. Here are seven to buy as market turbulence increases.

7 Low Volatility Stocks to Buy Right Now for Steady Returns

Medtronic

Moderna

Teladoc

Can these top health care stocks be the way to go amidst all the uncertainty in the stock market now?

Best Stocks To Invest In Right Now? 5 Health Care Stocks In Focus

Regeneron has grown at a rapid pace over the past few years, but still has room to grow due to its great management team and strong pipeline.

Regeneron: Large Upside Even After Recent Growth

Let's see if Regeneron Pharmaceuticals, Inc. (REGN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Is Regeneron Pharmaceuticals (REGN) Stock a Suitable Value Pick?

Sanofi

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab) in chronic spontaneous urticaria (CSU). The trial included CSU patients who don't respond to biologic treatment, Novartis AG (NYSE: NVS) / Roche Holdings AG's (OTC: RHHBY) Xolair (omalizumab).

Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial

Update on ongoing Dupixent ® (dupilumab) chronic spontaneous urticaria Phase 3 program

Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program

TARRYTOWN, N.Y. and PARIS, Feb. 18, 2022 /PRNewswire/ -- In a Phase 3 trial in patients refractory to omalizumab, Dupixent did not reach statistical significance in interim analysis despite numeric improvements observed across key endpoints; trial will be stopped due to futility Positive results from a previous Phase 3 trial in biologic-naïve patients showed Dupixent significantly reduced itch and hives compared to standard-of-care antihistamines alone Companies remain committed to advancing Dupixent for patients with chronic spontaneous urticaria uncontrolled on antihistamines and are evaluating next steps Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced a Phase 3 trial (CUPID STUDY B) evaluating Dupixent® (dupilumab) in patients with chronic spontaneous urticaria (CSU) will stop due to futility, based on a pre-specified interim analysis.

Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program

They're already bringing in billions of dollars in revenue.

3 Top Biotech Stocks to Buy for the Long Haul

TARRYTOWN, N.Y., Feb. 11, 2022 /PRNewswire/ --  Trial met primary safety endpoint and no new safety signals seen through week 44 Results favored aflibercept 8 mg in visual acuity, drying and other anatomical measures through week 44 Phase 3 results in wet age-related macular degeneration and diabetic macular edema expected in the second half of 2022 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results from its Phase 2 proof-of-concept trial evaluating an investigational 8 mg high dose of aflibercept compared to the currently-approved 2 mg dose of EYLEA® (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD).

Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting

Abbott Labs

Alnylam Pharmaceuticals

Bristol-Myers

Cerner

Stryker

Waters

The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2021 portfolio earlier this week.

The Vanguard Health Care Fund's Top 5 Trades

The FDA has accepted for Priority Review the supplemental marketing application for Dupixent (dupilumab) for children aged six months to 5 years with moderate-to-severe atopic dermatitis. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

News for Regeneron Pharmaceuticals Stock (REGN)